What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Pharmacology
Saye Khoo spends much of his time researching Pharmacology, Internal medicine, Pharmacokinetics, Ritonavir and Immunology.
He has included themes like Nevirapine, Efavirenz, Intracellular and Reverse-transcriptase inhibitor in his Pharmacology study.
The various areas that Saye Khoo examines in his Internal medicine study include Gastroenterology, Endocrinology and Single-nucleotide polymorphism.
His Pharmacokinetics study integrates concerns from other disciplines, such as SLCO1B1 and Toxicity, Nephrotoxicity.
His work deals with themes such as P-glycoprotein, Lopinavir, HIV Protease Inhibitor, Saquinavir and Atazanavir, which intersect with Ritonavir.
His research integrates issues of Salvage therapy, Surrogate endpoint, Oncology and Antiretroviral therapy in his study of Immunology.
His most cited work include:
- British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 (1031 citations)
- Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. (970 citations)
- Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. (283 citations)
What are the main themes of his work throughout his whole career to date?
Saye Khoo mainly focuses on Pharmacology, Pharmacokinetics, Internal medicine, Ritonavir and Efavirenz.
His specific area of interest is Pharmacology, where Saye Khoo studies Drug.
Saye Khoo interconnects Pregnancy, Emtricitabine and Dosing in the investigation of issues within Pharmacokinetics.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Acquired immunodeficiency syndrome and Immunology.
His studies in Immunology integrate themes in fields like Peripheral blood mononuclear cell, Antiretroviral therapy and Virology.
His Ritonavir research is multidisciplinary, relying on both Darunavir, Lopinavir, Atazanavir and Saquinavir.
He most often published in these fields:
- Pharmacology (42.80%)
- Pharmacokinetics (33.67%)
- Internal medicine (29.01%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (29.01%)
- Pharmacokinetics (33.67%)
- Pharmacology (42.80%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Pharmacokinetics, Pharmacology, Dolutegravir and Efavirenz are his primary areas of study.
His Internal medicine research includes elements of Gastroenterology, Artemether/lumefantrine, Lumefantrine and Standard treatment.
His Pharmacokinetics research incorporates elements of Pharmacogenetics and Emtricitabine.
His biological study spans a wide range of topics, including Nitazoxanide and Long acting.
His research on Dolutegravir also deals with topics like
- Pregnancy together with Viral load, Obstetrics, Cord blood and Family medicine,
- Public health which intersects with area such as Pharmacovigilance.
The study incorporates disciplines such as Darunavir, Adverse effect, Malaria, Nevirapine and Pediatrics in addition to Efavirenz.
Between 2018 and 2021, his most popular works were:
- Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. (45 citations)
- Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). (19 citations)
- Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). (19 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Acquired immunodeficiency syndrome
- Disease
His primary areas of investigation include Efavirenz, Internal medicine, Drug, Adverse effect and Pharmacokinetics.
His Efavirenz research incorporates themes from Nevirapine and Darunavir.
The concepts of his Internal medicine study are interwoven with issues in Malaria, Oncology and Standard treatment.
His work deals with themes such as Intensive care medicine, Lopinavir, Coronavirus disease 2019 and Ritonavir, which intersect with Drug.
His study on Pharmacokinetics is covered under Pharmacology.
When carried out as part of a general Pharmacology research project, his work on Cmax is frequently linked to work in Context, therefore connecting diverse disciplines of study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
